Is GlycoMimetics, Inc. overvalued or undervalued?

As of 28 April 2022, the valuation grade for GlycoMimetics, Inc. moved from risky to does not qualify, indicating a significant decline in its investment attractiveness. The company is currently overvalued, as evidenced by its Price to Book Value of 3.71 and a negative EV to EBIT and EV to EBITDA of -0.29, which suggest that the market is pricing the stock at a premium despite its lack of profitability. Additionally, the Return on Equity (ROE) is alarmingly low at -650.50%, further underscoring the company's financial struggles.
In comparison to its peers, GlycoMimetics shows a P/E ratio of -5.9739, while DiaMedica Therapeutics, Inc. has a P/E of -12.5116, and Abeona Therapeutics, Inc. has a P/E of 5.4453, highlighting the relative valuation challenges faced by GlycoMimetics. The stock has performed exceptionally well year-to-date with a return of 5096.79%, significantly outpacing the S&P 500's 12.22% return, but this performance may not be sustainable given the underlying financial metrics.